Adnexus Therapeutics

Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director

Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director

November 28, 2006

Accomplished Drug Development Physician to Drive Clinical Advancement of Maturing Adnectin™ Product Pipeline

Waltham, MA, November 28, 2006 – Adnexus TherapeuticsTM today announced the expansion of its management team with the appointment of Bruce A. Silver, MD, FACP to the newly-created role of Medical Director. The advancement into Phase 2 of CT-322, the company’s lead product that is currently in Phase 1 development in oncology, will be among Dr. Silver’s responsibilities.

BIND Therapeutics, Inc.

BIND Biosciences Secures $12.4 Million Financing

BIND Biosciences Secures $12.4 Million Financing

June 29, 2010

Series C-1 Financing Enables BIND To Pursue Multi-product Strategy

BIND Therapeutics, Inc.

BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer

BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer

June 29, 2010

Brings Clinical Leadership as BIND Prepares for Product Candidates to Enter the Clinic

Helicos BioSciences Corporation

Helicos BioSciences Announces Launch of Diagnostics Business

Helicos BioSciences Announces Launch of Diagnostics Business

June 25, 2010

CAMBRIDGE, Mass., Jun 25, 2010 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that it is in the early stages of validating molecular diagnostic (MDx) tests that utilize its HeliScope(R) Single Molecule Sequencer. The HeliScope Sequencer's ability to sequence single molecules of natural, unamplified DNA or RNA simplifies the diagnostic testing workflow obviating the need for the amplification steps utilized by most genetic analysis methods.

Mascoma Corporation

Mascoma and Tamarack Energy Partner to Accelerate the Commercialization of Cellulosic Ethanol

Mascoma and Tamarack Energy Partner to Accelerate the Commercialization of Cellulosic Ethanol

November 29, 2006

Plans Underway to Open Facilities with Initial Focus on the State of New York

VisEn Medical, Inc.

VisEn Medical Establishes Program To Develop and Apply Fluorescence In Vivo Imaging Technologies In Pharmaceutical R&D

VisEn Medical Establishes Program To Develop and Apply Fluorescence In Vivo Imaging Technologies In Pharmaceutical R&D

November 29, 2006

Woburn, MA November 29, 2006 VisEn Medical, Inc. today announced that it has entered into a joint research program to expand the capabilities and accelerate the adoption of VisEn's in vivo fluorescence technologies in Eli Lilly and Companys research and development programs. Lilly has been working with VisEn's portfolio of in vivo fluorescence probes and Fluorescence Molecular Tomography (FMT) imaging systems as part of their new molecular imaging center and preclinical development programs.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Raises $48.5 Million in Series B Financing

Concert Pharmaceuticals Raises $48.5 Million in Series B Financing

November 30, 2006

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 30, 2006--Concert Pharmaceuticals, Inc., a pharmaceutical company developing novel small molecule drugs for unmet medical needs, announced today that a group of prominent funds has invested $48.5 million in its Series B financing. The round was led by new investor Flagship Ventures and included Brookside Capital Partners Fund, LP and New Leaf Venture Partners. Also participating in the financing were all previous investors, including Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners and QVT Fund LP.

Reed Business Information to Buy Online Lead Generation Business - BuyerZone

Reed Business Information to Buy Online Lead Generation Business - BuyerZone

December 4, 2006

NEW YORK--(BUSINESS WIRE)--Reed Business Information (RBI), a leading B2B publisher in the U.S. and part of Reed Elsevier, announced today it will acquire BuyerZone.com, Inc., (BuyerZone) an online lead generation business. The closing is expected to occur on or about January 1, 2007, after the requisite regulatory approval is obtained.

VisEn Medical, Inc.

Dr. Geoffrey S. Ginsburg Joins VisEn Medical's Scientific Advisory Board

Dr. Geoffrey S. Ginsburg Joins VisEn Medical's Scientific Advisory Board

December 7, 2006

Heritage in Genomic Profiling and Molecular Medicine Tightly Linked with VisEn's Molecular Imaging Technology Platforms and Development Programs

Woburn, MA December 7, 2006 VisEn Medical, Inc., a leader in fluorescence in vivo imaging of biologic and molecular activities from research through medicine, today announced that Geoffrey S. Ginsburg, M.D., Ph.D. has joined its Scientific Advisory Board.

Concert Pharmaceuticals, Inc.

Peter Barton Hutt Appointed to Concert Pharmaceuticals Board Of Directors

Peter Barton Hutt Appointed to Concert Pharmaceuticals Board Of Directors

December 11, 2006

Lexington, MA –December 11, 2006 – Concert Pharmaceuticals, Inc. announced today the appointment of Peter Barton Hutt as a member of its Board of Directors. Mr. Hutt is a senior counsel in the Washington, DC law firm of Covington and Burling, specializing in food and drug law. Previously, he was Chief Counsel for the Food and Drug Administration.